胸腺上皮肿瘤中CDH13基因启动子区甲基化检测的临床意义  

Clinical significance of CDH13 gene promoter methylation in thymic epithelial tumors

作　　者：陈晨[1] 陆璨[2] 陆前进 CHEN Chen LU Can LU Qianjin(Department of Thoracic Surgery, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China Department of Stomatology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, China Hunan Key Laboratory of Medical Epigenomies, Changsha, Hunan 410011, China)

机构地区：[1]中南大学湘雅二医院胸外科,湖南长沙410011 [2]中南大学湘雅医院口腔医学中心,湖南长沙410008 [3]医学表观基因组学湖南省重点实验室,湖南长沙410011

出　　处：《中国医学工程》2017年第9期1-5,共5页China Medical Engineering

摘　　要：目的观察胸腺上皮肿瘤(TETs)组织中CDH13基因启动子区甲基化情况,探索CDH13基因启动子甲基化与TETs肿瘤发生进展之间的关系。方法收集胸腺上皮肿瘤组织,采用巢式甲基化特异性聚合酶链式反应(MSP)技术检测CDH13基因启动子区甲基化状态,并分析其与临床病理之间的联系。结果 CDH13基因启动子区甲基化总检出率为37.8%;CDH13基因启动子区甲基化情况与患者性别、年龄以及是否合并重症肌无力无关(P>0.05);按照世界卫生组织(WHO)组织学分型,分化越差的TETs组织中CDH13基因启动子区甲基化发生率越高,大多数甲基化阳性结果均来自于B2/B3/C组,A/AB/B1组仅有少量甲基化阳性结果(P=0.002);按照Masaoka病理分期,Ⅰ+Ⅱ期肿瘤中CDH13基因启动子甲基化率明显低于Ⅲ+Ⅳ期(P=0.001)。结论 CDH13基因启动子区的异常甲基化与TETs肿瘤的病理分期和组织学分型密切相关。【Objective】To investigate the promoter methylation of CDH13 status in patients with thymic epithelial tumors（TETs）.【Methods】Nested methylation-specific polymerase chain reaction（nMSP） was performed to evaluate the promoter region methylation patterns of CDH13 in TETs. The correlation between CDH13 promoter methylation and clinicopathological data were analyzed.【Results】CDH13 promoter hypermethylation was detected in 37.8% of the patients with TETs. The methylation rate of CDH13 was significantly higher in B2/B3/C group and stage Ⅲ＋Ⅳ group, compared to A/AB/B1 group and stage Ⅰ＋Ⅱ group, respectively. No correlations were found between CDH13 promoter hypermethylation and age, gender, or the occurrence of myasthenia gravis（MG） symptoms（P〉0.05）.【Conclusion】CDH13 promoter methylation plays an important role in the development of TETs, and is closely related to the Masaoka staging and World Health Organization criteria.

关 键 词：胸腺上皮肿瘤 甲基化 DNA CDH13 

分 类 号：R736.3[医药卫生—肿瘤]